Bendeka Disease Interactions
There are 4 disease interactions with Bendeka (bendamustine).
Bendamustine (applies to Bendeka) hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Bendamustine injection should be used with caution in patients with hepatic impairment. Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.
References
- (2008) "Product Information. Treanda (bendamustine)." Cephalon Inc
Bendamustine (applies to Bendeka) renal impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Bendamustine injection should be used with caution in patients with mild or moderate renal impairment. Bendamustine injection should not be used in patients with CrCL < 40 mL/min.
References
- (2008) "Product Information. Treanda (bendamustine)." Cephalon Inc
Bendamustine (applies to Bendeka) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Infection - Bacterial/Fungal/Protozoal/Viral
Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.
References
- (2008) "Product Information. Treanda (bendamustine)." Cephalon Inc
- (2016) "Product Information. Bendeka (bendamustine)." Teva Pharmaceuticals USA
Bendamustine (applies to Bendeka) myelosuppression
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
Adult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death. Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections. Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.
References
- (2008) "Product Information. Treanda (bendamustine)." Cephalon Inc
Bendeka drug interactions
There are 276 drug interactions with Bendeka (bendamustine).
Bendeka alcohol/food interactions
There is 1 alcohol/food interaction with Bendeka (bendamustine).
More about Bendeka (bendamustine)
- Bendeka consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: alkylating agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.